NCT06028425View on ClinicalTrials.gov

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 23, 2023

Study Completion Date

December 23, 2023

Conditions

Healthy

Interventions

DRUG

LOXO-783

Administered orally.

Trial Locations (1)

32117

Fortrea Clinical Research Unit, Daytona Beach

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY